Posted: Feb 24, 2012
CBR® (Cord Blood Registry®) is not just the largest, most experienced stem cell bank – we’re dedicated to connecting clients with clinical trials evaluating the regenerative potential of newborn stem cells.
CBR is the exclusive partner for a growing number of clinical researchers focusing on the use of a child’s own cord blood stem cells to help treat pediatric brain injury and acquired hearing loss.
To ensure consistency in cord blood stem cell processing, storage and release for infusion, three separate trials have included CBR in their FDA-authorized protocol—including two at the University of Texas Health Science Center at Houston (UTHealth) working in partnership with Children’s Memorial Hermann Hospital, and a third at Georgia Health Sciences University, home of the Medical College of Georgia (MCG). This makes CBR the only family stem cell bank pairing researchers with prospective patients for these studies.
These multi-year studies are a first step toward moving pre-clinical or animal research of cord blood stem cells into clinical trials in patients. Through the CBR Center for Regenerative Medicine, CBR will continue to partner with physicians who are interested in advancing cellular therapies in regenerative applications.
“The benefits of cord blood stem cells being very young, easy to obtain, unspecialized cells which have had limited exposure to environmental toxins or infectious diseases and easy to store for long terms without any loss of function, make them an attractive source for cellular therapy researchers today,” said Heather Brown, MS, CGC, Vice President of Scientific & Medical Affairs at Cord Blood Registry. “We are encouraged to see interest from such diverse researchers from neurosurgeons to endocrinologists and cardiac specialists.”
See more information on current clinical trials.